Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Multiomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs
Xiao-Feng Chen, … , Yan Guo, Tie-Lin Yang
Xiao-Feng Chen, … , Yan Guo, Tie-Lin Yang
Published September 3, 2020
Citation Information: JCI Insight. 2020;5(17):e136477. https://doi.org/10.1172/jci.insight.136477.
View: Text | PDF
Research Article Genetics

Multiomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs

  • Text
  • PDF
Abstract

More than 90% of autoimmune-associated variants are located in noncoding regions, leading to challenges in deciphering the underlying causal roles of functional variants and genes and biological mechanisms. Therefore, to reduce the gap between traditional genetic findings and mechanistic understanding of disease etiologies and clinical drug development, it is important to translate systematically the regulatory mechanisms underlying noncoding variants. Here, we prioritized functional noncoding SNPs with regulatory gene targets associated with 19 autoimmune diseases by incorporating hundreds of immune cell–specific multiomics data. The prioritized SNPs are associated with transcription factor (TF) binding, histone modification, or chromatin accessibility, indicating their allele-specific regulatory roles. Their target genes are significantly enriched in immunologically related pathways and other known immunologically related functions. We found that 90.1% of target genes are regulated by distal SNPs involving several TFs (e.g., the DNA-binding protein CCCTC-binding factor [CTCF]), suggesting the importance of long-range chromatin interaction in autoimmune diseases. Moreover, we predicted potential drug targets for autoimmune diseases, including 2 genes (NFKB1 and SH2B3) with known drug indications on other diseases, highlighting their potential drug repurposing opportunities. Taken together, these findings may provide useful information for future experimental follow-up and drug applications on autoimmune diseases.

Authors

Xiao-Feng Chen, Ming-Rui Guo, Yuan-Yuan Duan, Feng Jiang, Hao Wu, Shan-Shan Dong, Xiao-Rong Zhou, Hlaing Nwe Thynn, Cong-Cong Liu, Lin Zhang, Yan Guo, Tie-Lin Yang

×

Figure 8

Predicted new targets with potential drug repurposing opportunities for autoimmune diseases.

Options: View larger image (or click on image) Download as PowerPoint
Predicted new targets with potential drug repurposing opportunities for ...
(A–C) Predicted new candidate drug targets on 3 autoimmune diseases. The orange rectangle shows predicted new drug genes. Genes with known indications on other autoimmune or nonautoimmune diseases are shown in black or blue. Genes without known drug target indications are shown in red. Supplemental Figure 15 shows predicted new candidate drug targets on 4 other autoimmune diseases. See Supplemental Table 16 for detailed drug indication information.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts